Granted Patent
B2
US 12,404,492 · App. 17/862,797 · Granted Sep 2, 2025
Methods for enhancing efficacy of therapeutic immune cells
Assignee:
NATIONAL UNIVERSITY OF SINGAPORE
C12N5/0646A61K40/11A61K40/15A61K40/31A61K40/4211A61K40/4224C07K16/2809C07K16/2833C07K16/289C12N5/0636A61K2239/48C07K2319/03C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.
Claims (25)
1. A composition comprising one or more recombinant polynucleotide molecules, the composition comprising
a first recombinant polynucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a first binding domain and a signaling domain; and
a second recombinant polynucleotide sequence encoding a target-binding molecule linked to a localizing domain, wherein the target-binding molecule linked to the localizing domain comprises a second binding domain and the localizing domain comprising an ER retention sequence, a Golgi retention sequence, or a PEST sequence,
wherein the second recombinant polynucleotide sequence comprises, from 5′ terminus to 3′ terminus, a first nucleotide sequence encoding the second binding domain, a second nucleotide sequence encoding a peptide linker, and a third nucleotide sequence encoding the localizing domain, and wherein the peptide linker comprises at least 5 amino acids, and
wherein the first binding domain is capable of binding to a molecule expressed on the surface of a cancer cell that is also expressed in an immune cell, and the second binding domain is capable of binding to the same molecule and suppressing its expression in the immune cell.
2. The composition of claim 1 , wherein the first recombinant polynucleotide sequence and the second recombinant polynucleotide sequence are on the same polynucleotide molecule.
3. The composition of claim 2 , further comprising an internal ribosomal entry site or a 2A peptide-coding region site between the first recombinant polynucleotide sequence encoding the CAR and the second recombinant polynucleotide sequence encoding the target-binding molecule linked to a localizing domain.
4. The composition of claim 1 , wherein the localizing domain comprises an ER retention sequence.
5. The composition of claim 4 , wherein the ER retention sequence comprises a KDEL amino acid sequence.
6. The composition of claim 4 , wherein the ER retention sequence comprises a KKXX amino acid sequence, wherein X represents any amino acid.
7. The composition of claim 1 , wherein the localizing domain comprises a Golgi retention sequence.
8. The composition of claim 7 , wherein the Golgi retention sequence comprises a YQRL amino acid sequence.
9. The composition of claim 1 , wherein the localizing domain comprises a PEST sequence.
10. The composition of claim 1 , wherein the polynucleotide is a vector.
11. The composition of claim 1 , wherein the polynucleotide is a lentiviral vector.
12. The composition of claim 1 , wherein the first or the second binding domain comprises a single chain binding domain.
13. The composition of claim 12 , wherein the single chain binding domain is a single chain variable fragment (scFv).
14. The composition of claim 1 , wherein the target-binding molecule linked to a localizing domain further comprises a transmembrane domain.
15. The composition of claim 14 , wherein the transmembrane domain is a CD8 transmembrane domain.
16. The composition of claim 1 , wherein the second binding domain is identical to the first binding domain.
17. The composition of claim 1 , wherein the second binding domain and the first binding domain are different.
18. The composition of claim 1 , wherein the signaling domain comprises a CD3ζ, a Fe, a DAP10, or a DAP12 domain.
19. The composition of claim 1 , wherein the CAR further comprises a co-stimulatory domain.
20. The composition of claim 1 , wherein the second recombinant polynucleotide sequence further comprises a nucleotide sequence encoding a signal peptide.
21. The composition of claim 1 , wherein the first binding domain is a first single chain variable fragment (scFv) and the second binding domain is a second scFv.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 17, 2022
From: CAMPANA, DARIO; KAMIYA, TAKAHIRO
To: NATIONAL UNIVERSITY OF SINGAPORE
Reel/Frame 060835/0591 →
Continuity (5)
Continuation
15548577
Provisional Application
62130970
· Mar 10, 2015
Provisional Application
62112765
· Feb 6, 2015
References Cited (319)
US 4946778A
· Ladner et al.
· 1990
[cited by applicant]
US 5260203A
· Ladner et al.
· 1993
[cited by applicant]
US 7887805B2
· Pedersen et al.
· 2011
[cited by applicant]
US 8119775B2
· Moretta et al.
· 2012
[cited by applicant]
US 8399645B2
· Campana et al.
· 2013
[cited by applicant]
US 8580714B2
· Almagro et al.
· 2013
[cited by applicant]
US 8614307B2
· Moretta et al.
· 2013
[cited by applicant]
US 8637258B2
· Padkjaer et al.
· 2014
[cited by applicant]
US 8796427B2
· Spee et al.
· 2014
[cited by applicant]
US 8981065B2
· Moretta et al.
· 2015
[cited by applicant]
US 9181527B2
· Sentman
· 2015
[cited by applicant]
US 9273283B2
· Sentman
· 2016
[cited by applicant]
US 9422368B2
· Spee et al.
· 2016
[cited by applicant]
US 9683042B2
· Lee et al.
· 2017
[cited by applicant]
US 9902936B2
· Moretta et al.
· 2018
[cited by applicant]
US 20060034834A1
· Marasco et al.
· 2006
[cited by applicant]
US 20070036773A1
· Cooper et al.
· 2007
[cited by applicant]
US 20090196850A1
· Romagne et al.
· 2009
[cited by applicant]
US 20130266551A1
· Campana et al.
· 2013
[cited by applicant]
US 20170335331A1
· Zhao et al.
· 2017
[cited by applicant]
US 20190002912A1
· Lu et al.
· 2019
[cited by applicant]
US 20190038733A1
· Campana et al.
· 2019
[cited by applicant]
US 20190345217A1
· Ma et al.
· 2019
[cited by applicant]
US 20200087398A1
· Qasim et al.
· 2020
[cited by applicant]
CA 2937157A1
· 2018
[cited by applicant]
CN 107709548A
· 2018
[cited by applicant]
CN 113713091A
· 2021
[cited by applicant]
CN 107709548B
· 2022
[cited by applicant]
CN 115029362A
· 2022
[cited by applicant]
EP 0404097A2
· 1990
[cited by applicant]
EP 2247619A1
· 2010
[cited by applicant]
EP 3169773A2
· 2017
[cited by applicant]
EP 3322801A1
· 2018
[cited by applicant]
EP 3359168A1
· 2018
[cited by applicant]
EP 3474867A1
· 2019
[cited by applicant]
EP 3568467A1
· 2019
[cited by applicant]
JP H03219896A
· 1991
[cited by applicant]
JP H09501824A
· 1997
[cited by applicant]
JP 2001516766A
· 2001
[cited by applicant]
JP 2004529610A
· 2004
[cited by applicant]
JP 2008506368A
· 2008
[cited by applicant]
JP 2008518021A
· 2008
[cited by applicant]
JP 2009511495A
· 2009
[cited by applicant]
JP 2010537671A
· 2010
[cited by applicant]
JP 2011510047A
· 2011
[cited by applicant]
JP 2014507118A
· 2014
[cited by applicant]
JP 6895380B2
· 2021
[cited by applicant]
JP 2021137024A
· 2021
[cited by applicant]
WO WO8801649A1
· 1988
[cited by applicant]
WO WO9311161A1
· 1993
[cited by applicant]
WO WO9914353A2
· 1999
[cited by applicant]
WO WO03051926A2
· 2003
[cited by applicant]
WO WO2005017163A2
· 2005
[cited by applicant]
WO WO2006003179A2
· 2006
[cited by applicant]
WO WO2009092805A1
· 2009
[cited by applicant]
WO WO2012079000A1
· 2012
[cited by applicant]
WO WO2013126712A1
· 2013
[cited by applicant]
WO WO2014011984A1
· 2014
[cited by applicant]
WO WO2014124143A1
· 2014
[cited by applicant]
WO WO2014134165A1
· 2014
[cited by applicant]
WO WO2014159940A1
· 2014
[cited by applicant]
WO WO2015075468A1
· 2015
[cited by applicant]
WO WO2015121454A1
· 2015
[cited by applicant]
WO WO2015150771A1
· 2015
[cited by applicant]
WO WO2016055551A1
· 2016
[cited by applicant]
WO WO2016102965A1
· 2016
[cited by applicant]
WO WO2016126213A1
· 2016
[cited by applicant]
WO WO2017213979A1
· 2017
[cited by applicant]
WO WO2018027036A1
· 2018
[cited by applicant]
WO WO2019032916A1
· 2019
[cited by applicant]
Janeway CA Jr, Travers P, Walport M, et al. , Immunobiology: The Immune System in Health and Disease. 5th edition New York: Garland Science; 2001. (Year: 2001).
[cited by examiner]
Khan et al., Protein disulfide isomerase a multifunctional protein with multiple physiological roles. Front. Chem., Aug. 25, 2014 Sec. Cellular Biochemistry vol. 2—2014 (Year: 2014).
[cited by examiner]
Brown et al. Novel Treatments for Chronic Lymphocytic Leukemia and Moving Forward. American Society of Clinical Oncology Educational Book, pp. e317-e325 (2014). Retrieved at URL: https://ascopubs.org/doi/pdfdirect/10.14…
[cited by applicant]
Caruana et al. From Monoclonal Antibodies to Chimeric Antigen Receptors for the Treatment of Human Malignancies. Semin Oncol. Oct. 2014 ; 41(5): 661-666.
[cited by applicant]
Certified copy of PCT/US2016/019953 priority document U.S. Appl. No. 62/121,842, MA, Yupo et al., inventors, filed Feb. 27, 2015.
[cited by applicant]
Feng et al. Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 Car T Cells. Stem Cell Reviews and Reports (2021) 17:652-661. Published online Jan. 6, 2021.
[cited by applicant]
Fujiwara, et al. Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors. Pharmaceuticals (Basel). Dec. 2014; 7(12): 1049-1068.
[cited by applicant]
Glienke et al. Advantages and applications of CAR-expressing natural killer cells. Frontiers in Pharmacology, vol. 6, Article 21 (Feb. 12, 2015). 7 pages.
[cited by applicant]
Guo et al. Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment. Cell Mol Immunol 17, 430-432 (2020).
[cited by applicant]
Hishima et al. CD5 Expression in Thymic Carcinoma. American Journal of Pathology, vol. 145, No. 2, pp. 268-275 (Aug. 1994).
[cited by applicant]
Imboden et al. Stimulation of CD5 enhances signal transduction by the T cell antigen receptor. J Clin Invest. 1990. 85:130-134.
[cited by applicant]
Jena et al., Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 116:1035-1044 (2010).
[cited by applicant]
Kapp et al. Chapter 1: Post-Targeting Functions of Signal Peptides. In Protein Transport into the Endoplasmic Reticulum, Zimmerman, ed., 2009, Landes Bioscience. 13 pages. Retrieved at URL: https://www.ncbi.nlm.nih.gov/…
[cited by applicant]
Lemaistre et al. Phase I Trial of H65-RTA Immunoconjugate in Patients With Cutaneous T-cell Lymphoma. Blood, vol. 78, No. 5 (Sep. 1), 1991: pp. 1173-1182.
[cited by applicant]
Lewis et al. The immunophenotype of pre-TALL/LBL revisited. Experimental and Molecular Pathology 81 (2006) 162-165. Available online Aug. 14, 2006.
[cited by applicant]
Li et al. Flow Cytometry in the Differential Diagnosis of Lymphocyte-Rich Thymoma From Precursor T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Am J Clin Pathol 2004;121:268-274.
[cited by applicant]
Litzow et al. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015; 126(7):833-841. Retrieved at URL: https://www.academia.edu/download/47911039/j.yexmp.2006.06.00620160809-3503-eb5sgz.pdf.
[cited by applicant]
Liu et al. [NK cell surface receptors and their research progress—review]. Zhongguo shi yan xue ye xue za zhi. Aug. 2012;20(4):1034-1038. English abstract only. Retrieved at URL: https://pubmed.ncbi.nlm.nih.gov/22931679…
[cited by applicant]
Morris et al. Antibody-based therapy of leukaemia. Expert Rev Mol Med. Sep. 30, 2009; 11: e29.
[cited by applicant]
Pinz et al. Preclinical targeting of human T cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia, accepted article preview (Nov. 3, 2015). Retrieved at URL: https://www.rese…
[cited by applicant]
Rezvani et al. The Application of Natural Killer Cell immunotherapy for the Treatment of Cancer. Frontiers in Immunology, vol. 6, Article 578 (Nov. 17, 2015). 13 pages.
[cited by applicant]
Roitt et al. Roitt's Essential Immunology. 12th Edition, Wiley-Blackwell, Chapter 4 (2012).
[cited by applicant]
Sommermeyer, et al., Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30(2):492-500 (2016).
[cited by applicant]
U.S. Appl. No. 17/862,721 Notice of Allowance dated Jun. 9, 2023.
[cited by applicant]
Zhong-Fu et al. Clinical Applications of NK Cells in Tumor Immunotherapy. Chinese Journal of Biochemistry and Molecular Biology 27(12):1088-1093 (Dec. 2011). With English translation.
[cited by applicant]
Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_143513_us-15-548-577-37.rag. Search run on Jan. 7, 2019. Copy retrieved Sep. 11, 2019 at http://score.uspto.gov/ScoreAccessWeb/getIte…
[cited by applicant]
Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_143514_us-15-548-577-36.rapbm. Search run on Jan. 7, 2019. Copy retrieved Sep. 11, 2019 at http://score.uspto.gov/ScoreAccessWeb/getI…
[cited by applicant]
Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_143513_us-15-548-577-37.rag. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem…
[cited by applicant]
Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_143514_us-15-548-577-36.rapbm. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getIt…
[cited by applicant]
Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_143514_us-15-548-577-37.rai. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem…
[cited by applicant]
Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_145543_us-15-548-577-32.rag. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem…
[cited by applicant]
Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_145544_us-15-548-577-32.rai. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem…
[cited by applicant]
Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_145544_us-15-548-577-32.rapbm. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getIt…
[cited by applicant]
Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_145544_us-15-548-577-33.rai. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem…
[cited by applicant]
Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_145544_us-15-548-577-33.rapbm. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getIt…
[cited by applicant]
Chen, Kevin H., et al. Novel Anti-cd3 Chimeric Antigen Receptor Targeting of Aggressive T Cell Malignancies. Oncotarget, vol. 7, 56219-56232 (2016).
[cited by applicant]
Kipriyanov, Sergey M., et al. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Engineering, vol. 10, 445-453 (199…
[cited by applicant]
U.S. Appl. No. 18/295,226 Office Action dated Aug. 2, 2024.
[cited by applicant]
EP22180254.9 Extended European Search Report dated Jan. 16, 2023.
[cited by applicant]
U.S. Appl. No. 16/100,117 Notice of Allowance dated Feb. 17, 2023.
[cited by applicant]
U.S. Appl. No. 16/100,117 Notice of Allowance dated Jan. 5, 2023.
[cited by applicant]
U.S. Appl. No. 17/862,721 Notice of Allowance dated Feb. 15, 2023.
[cited by applicant]
U.S. Appl. No. 17/862,721 Office Action dated Jan. 5, 2023.
[cited by applicant]
Alanen et al., Beyond KDEL: the role of positions 5 and 6 in determining ER localization. J. Mol. Biol. (2011) 409, 291-297. Available online Apr. 6, 2011.
[cited by applicant]
Alarcon et al., Assembly of the human T cell receptor-CD3 complex takes place in the endoplasmic reticulum and involves intermediary complexes between the CD3-gamma.delta.epsilon core and single T cell receptor alpha or…
[cited by applicant]
Almagro, Juan C., Fransson, Johan. Humanization of antibodies. Frontiers in Bioscience 13;1619-1633 (Jan. 1, 2008).
[cited by applicant]
Altschul et al. Basic local alignment search tool. J Mol Biol 215(3):403-410 (1990).
[cited by applicant]
Anti-CD3 epsilon [OKT-3 (muromonab)]. Absolute Antibody. Website. Copyright 2021. Retrieved Dec. 26, 2021 at URL: https://absoluteantibody.com/product/anti-cd3-epsilon-okt-3 -. . . 4 pages.
[cited by applicant]
Anti-CD3D monoclonal antibody, clone PLU4 (DCABH-10124). Product Information. CD Creative Diagnostics. Publication date unknown. 2 pages.
[cited by applicant]
Anti-TCR [BMA031]. Absolute Antibody. Website. Copyright 2021. Retrieved Dec. 26, 2021 at URL: https://absoluteantibody.com/product/anti-tcr-bma031/ 4 pages.
[cited by applicant]
Anwer et al., Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review, Immunotherapy, Jan. 2017;9(2):123-130.
[cited by applicant]
APPELBAUM. Haematopoietic cell transplantation as immunotherapy. Nature, vol. 411, pp. 385-389 (2001).
[cited by applicant]
Arafat et al. Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target. Cancer Gene Therapy, vol. 7, No. 9, 2000: pp. 1250-1256.
[cited by applicant]
Arase et al. Recognition of virus infected cells by NK cells (w/ English abstract). Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, vol. 54, No. 2, pp. 153-160 (2004).
[cited by applicant]
Austyn et al. T cell activation by anti-CD3 antibodies: function of Fc receptors on B cell blasts, but not resting B cells, and CD18 on the responding T cells. Eur J Immunol 17:1329-1335 (1987).
[cited by applicant]
Böldicke et al., Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the Er, J. Cell. Mol. Med., 11(1):54-70 (2007).
[cited by applicant]
Böldicke et al. Functional inhibition of transitory proteins by intrabody-mediated retention in the endoplasmatic reticulum. Methods 56 (2012) 338-350. Available online Oct. 20, 2011.
[cited by applicant]
Bleakley et al., Molecules and mechanisms of the graft-versus-leukaemia effect, Nature Reviews, Cancer, May 2004;4(5):371-80.
[cited by applicant]
Boettcher et al., Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR, Mol Cell. May 21, 2015;58:575-85.
[cited by applicant]
Brentjens et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. Mar. 20, 2013;5(177):177ra38. 9 pages.
[cited by applicant]
Brentjens et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. Mar. 2003;9(3):279-86.
[cited by applicant]
Brentjens et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. Nov. 3, 2011;118(18):4817-28. Prepublished…
[cited by applicant]
Brudno et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-…
[cited by applicant]
Burns et al. Two monoclonal anti-human T lymphocyte antibodies have similar biologic effects and recognize the same cell surface antigen. J Immunol 1982; 129:1451-1457.
[cited by applicant]
Campana et al. 4-1BB chimeric antigen receptors. Cancer J. Mar.-Apr. 2014;20(2):134-40.
[cited by applicant]
Ceuppens et al. Failure of OKT3 monoclonal antibody to induce lymphocyte mitogenesis: a familial defect in monocyte helper function. J Immunol, vol. 134, No. 3, pp. 1498-1502 (Mar. 1985).
[cited by applicant]
Chang et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 73(6):1777-86 (Mar. 15, 2013). Published online Jan. 9, 2013.
[cited by applicant]
Chen et al., Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with No. response to donor lymphocyte infusions after haploid…
[cited by applicant]
Clevers et al., The T cell receptor/CD3 complex: a dynamic protein ensemble, Annual Review of Immunology, 1988;6:629-62.
[cited by applicant]
Clift, Dean, et al.“A Method for the Acute and Rapid Degradation of Endogenous Proteins”, Elsevier Inc., Cell 172, Dec. 14, 2017, pp. 1692-1706.
[cited by applicant]
Cooley et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 116 (14): 2411-2419.
[cited by applicant]
Cooper, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. Feb. 15, 2003;101(4):1637- 44. Epub Oct. 10, 2002.
[cited by applicant]
Dai et al., Tolerance and efficacy of autologous or donor-derived T cells expression CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncolmmunology, 4:11, e1027469 (2015). 12 pages.
[cited by applicant]
Davila. Efficacy and toxicity management of 19-28z Car T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra25 (2014).
[cited by applicant]
Dotti et al. Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells. Immunol Rev. 257(1):35 pgs (2014).
[cited by applicant]
EP16746922.0 Extended European Search Report dated Sep. 21, 2018.
[cited by applicant]
EP18844536.5 Extended European Search Report dated Mar. 18, 2021.
[cited by applicant]
Eshhar et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. P…
[cited by applicant]
Eyquem et al., Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature. Mar. 2, 2017; 543(7643): 113-117.
[cited by applicant]
Gale. Cellular and Molecular Basis of Cancer. Merck Manual Professional Version. Last full review/revision Nov. 2020. Content last modified Nov. 2020. Retrieved Jan. 8, 2021 at URL: https://www.merckmanuals.com/professi…
[cited by applicant]
Gan et al. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers 2020, 12, 1872. Published Jul. 11, 2020. 22 pages.
[cited by applicant]
Gao et al. Retention mechanisms for ER and Golgi membrane proteins. Trends in Plant Science, vol. 19, Issue 8, pp. 508-515 (Aug. 2014).
[cited by applicant]
Geiger et al. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 98(8):2364-2371 (2001).
[cited by applicant]
Geiger et al. The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes. The Journal of Immunology, 1999, 162: 5931-5939.
[cited by applicant]
Ghosh et al., Donor CD19 Car T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity, Nat Med. Feb. 2017 ; 23(2): 242-249.
[cited by applicant]
Giebel et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 102 (3): 814-819.
[cited by applicant]
Grimshaw, B.D. et al., BGST Abstract Mar. 9, 2012, abstract P023, “Creating a ‘null’ T cell for use in adoptive immunotherapy”, British Society for Gene and Cell Therapy 2012, hltp://www.bsqct.orq, Human Gene Therapy, 2…
[cited by applicant]
Grimshaw. Developing a universal T cell for use in adoptive immunotherapy (thesis), University College London (2015). Retrieved Aug. 22, 2022 at URL: http://discovery.ucl.ac.uk/1470207/1/Grimshaw%20Ben%20Thesis.pdf. 267…
[cited by applicant]
Grimshaw et al. Creating a Null T Cell for Adoptive Immunotherapy. Poster. Mar. 9, 2012. One page.
[cited by applicant]
Grovender et al. Single-chain antibody fragment-based adsorbent for the extracorporeal removal of β2-microglobulin. Kidney International, vol. 65 (2004), pp. 310-322.
[cited by applicant]
Grupp et al. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. N Engl J Med 368; 16, pp. 1509-1508 (Apr. 18, 2013). With correction published N. Engl J. Med (2016) 374(10) 998.
[cited by applicant]
Haegert et al. Co-expression of surface immunoglobulin and T3 on hairy cells. Scand J Haematol 1986;37:196-202.
[cited by applicant]
Haynes et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002; 169:5780-5786.
[cited by applicant]
Haynes et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood. Nov. 1, 2002;100(9):3155-63. Published online Jul. 5, 2002.
[cited by applicant]
Hegde, M. et al., “Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma”, Molecular Therapy, 2013, vol. 21, pp. 2087-2101.
[cited by applicant]
Hegde, M. et al., Supplementary Material for “Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma”, Molecular Therapy, 2013, vol. 21, pp. 2087…
[cited by applicant]
Hexham et al. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins. Molecular Immunology 38 (2001) 397-408.
[cited by applicant]
Holliger et al. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA, vol. 90, pp. 6444-6448 (Jul. 1993).
[cited by applicant]
Hombach et al. Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28…
[cited by applicant]
Imai et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 18, 676-684.
[cited by applicant]
Imai et al. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 106 (1): 376-383.
[cited by applicant]
Imamura. M. et al., “Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15”, Blood, 2014, vol. 124, pp. 1081-1088.
[cited by applicant]
Imamura. M. et al., Supplementary Material for “Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15”, Blood, 2014, vol. 124, pp. 1081-1088. Retrieved Jan. 6, 202…
[cited by applicant]
Jackson et al., Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum, EMBO J. Oct. 1990; 9(10): 3153-3162.
[cited by applicant]
Joshi et al. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. mAbs, vol. 4, Issue 6, pp. 686-693 (2012). Published …
[cited by applicant]
Kalos, et al., “T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia”, Science Translation Medicine 3.95 (2011):95ra73-95ra73.
[cited by applicant]
Kamiya, et al., “A novel method to generate T-cell receptor-deficient antigen receptor T cells,” Blood Advances, vol. 2, No. 5, Mar. 13, 2018, pp. 517-528.
[cited by applicant]
Kamiya et al. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest. 2019; 129(5):2094-2106.
[cited by applicant]
Kloss, C.C. et al., Supplementary Text and Figures for “Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells”, Nature Biotechnology, 2013, vol. 31, pp. 71-…
[cited by applicant]
Kloss. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Technology, vol. 31, No. 1, pp. 71-75 (Jan. 2013). Published online Dec. 16, 2012.
[cited by applicant]
Kochenderfer et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720. Pub…
[cited by applicant]
Kochenderfer et al., Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, Journal o…
[cited by applicant]
Kochenderfer et al., Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation, Blood. 2013;122(25):4129-4139.
[cited by applicant]
Kolb et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, vol. 86. No. 5 (Sep. 1), 1995: pp. 2041-2050.
[cited by applicant]
Kotteas et al. Immunotherapy for pancreatic cancer. J Cancer Res Clin Oncol (2016) 142:1795-1805. Published online Feb. 3, 2016.
[cited by applicant]
Kudo et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res 74(1):93-103 (2013).
[cited by applicant]
Lanitis et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 1(1):43-53 (2013).
[cited by applicant]
Lee, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. Jul. 10, 2014;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub May 29, 2014.
[cited by applicant]
Lee et al., T cells expressing CD 19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet, Feb. 7, 2015; 385 (9967); pp. 517-528. Epub Oct. 1…
[cited by applicant]
Lo et al. Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. Molecular Immunology 45 (2008) 1276-1287. Available online Oct. 24, 2007.
[cited by applicant]
Lorentzen et al. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia. Scandinavian Journal of Immunology, 2015, 82, 307-319.
[cited by applicant]
Maciocia et al. A simple protein-based method for generation of ‘off the shelf’ allogeneic chimeric antigen receptor T-cells. Database Embase [Online] 1-15, Elsevier Science Publishers, Amsterdam, NL (May 1, 2018). Abst…
[cited by applicant]
Maciocia et al. A simple protein-based method for generation of ‘off the shelf’ allogeneic chimeric antigen receptor T-cells. Molecular Therapy, vol. 26, No. 5, Supplement 1, pp. 296-297 (May 2018). Cell Press NLD. May …
[cited by applicant]
MacLeod et al., Integration of a CD19 Car into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells, Molecular Therapy, vol. 25, No. 4, pp. 949-961, Apr. 2017.
[cited by applicant]
Maher et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotech 20(1):70-75 (2002).
[cited by applicant]
Marasco et al. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. PNAS USA 90:7889-7893 (1993).
[cited by applicant]
Marschall, Andrea LJ, et al.“Specific in vivo knockdown of protein function by intrabodies”, Taylor & Francis Group, LLC, Nov./Dec. 2015, vol. 7, Issue 6, pp. 1010-1035.
[cited by applicant]
Maude, et al., Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N. Engl J. Med (2014) 371(16) 1507-1517. With correction published N. Engl J. Med 374(10): 998 (2016).
[cited by applicant]
Miller et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051-3057 (2005).
[cited by applicant]
Miller. Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 247-253.
[cited by applicant]
Milone et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17:1453-1464 (2009).
[cited by applicant]
Munro et al., A C-terminal signal prevents secretion of luminal ER proteins, Cell. Mar. 13, 1987;48:899-907. Retrieved Apr. 7, 2022 at URL: https://bio.davidson.edu/molecular/MunPelham/mufixed.html.
[cited by applicant]
Kochenderfer et al., Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 (Blood, 2010, 116:4099-4102) (Year: 2010).
[cited by applicant]
Needleman et al. A general method applicable to the search for similarities in the amino acid sequence of two proteins. Journal of molecular biology 48(3):443-453 (1970).
[cited by applicant]
Neelapu et al., Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma, N Engl J Med 377;26 pp. 2531-2544 (Dec. 28, 2017).
[cited by applicant]
Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12(4):252-264 (2012).
[cited by applicant]
Park et al. Are all chimeric antigen receptors created equal? J Clin Oncol. Feb. 20, 2015;33(6):651-3. Epub Jan. 20, 2015.
[cited by applicant]
Park et al., CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date, Blood. 2016; 127(26):3312-3320.
[cited by applicant]
PCT/SG2016/050063 International Search Report and Written Opinion dated May 9, 2016.
[cited by applicant]
PCT/US2018/046137 International Search Report and Written Opinion dated Oct. 29, 2018.
[cited by applicant]
Pearson and Lipman, Improved tools for biological sequence comparison, Proc. Nat. Acad Sci USA., 85:2444-2448, (1988).
[cited by applicant]
Peipp et al. A Recombinant CD7-specific Single-Chain Immunotoxin Is a Potent Inducer of Apoptosis in Acute Leukemic T Cells. Cancer Research 62, pp. 2848-2855 (May 15, 2002).
[cited by applicant]
Png, et al., “Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies”, Blood Advances, vol. 1, No. 25, Nov. 28, 2017, pp. 2348-2360.
[cited by applicant]
Poirot et al. Multiplex Genome-Edited T-cell Manufacturing Platform for Off-the-Shelf Adoptive T-cell Immunotherapies. Cancer Research 75(18):3853-3864 (2015).
[cited by applicant]
Porter et al., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733 (2011). With correction published N. Engl J. Med (2016) 374(10) 998.
[cited by applicant]
Porter et al. Induction of Graft-versus-Host Disease as Immunotherapy for Relapsed Chronic Myeloid Leukemia. N Engl J Med 1994; 330:100-106.
[cited by applicant]
Qasim et al., Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CART cells. Sci. Transl. Med. 9, eaaj2013 (2017). With Erratum. Erratum retrieved Apr. 7, 2022 at URL: https://www.science.…
[cited by applicant]
Reshef et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 367;3 pp. 135-145 (Jul. 12, 2012).
[cited by applicant]
Rosenberg et al. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348(6230):62-68 (2015).
[cited by applicant]
Rossig, C. et al., “Genetic modification of T lymphocytes for adoptive immunotherapy”, Molecular Therapy, 2004, vol. 10, pp. 5-18.
[cited by applicant]
Rowley, J. et al., “Expression of IL-15RA or an IL-15/1L-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis”, European Journal of Immunology, 2009, vol. 39, pp. 491-506.
[cited by applicant]
Rowley, J. et al., Supplementary Information for “Expression of IL-15RA or an IL-15/1L-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis”, European Journal of Immunology, 2009, vol. 39, …
[cited by applicant]
Rubnitz et al. NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. J Clin Oncol. Feb. 20, 2010; 28(6): 955-959.
[cited by applicant]
Rudikoff, et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
[cited by applicant]
Ruggeri et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097-2100 (2002).
[cited by applicant]
Sadelain et al. The Basic Principles of Chimeric Antigen Receptor Design. Cancer Discov. Apr. 2013 ; 3(4): 388-398.
[cited by applicant]
Sadelain et al. Therapeutic T cell engineering. Nature 545:423-431 (2017).
[cited by applicant]
Sanz, L. et al., “Antibodies and gene therapy: teaching old ‘magic bullets’ new tricks”, Trends in Immunology, 2004, vol. 25, pp. 85-91.
[cited by applicant]
Sato et al. Single domain intrabodies against WASP inhibit TCR-induced immune responses in transgenic mice T cells. Sci Rep. Oct. 21, 2013;3:3003. 10 pages.
[cited by applicant]
Schumann, et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. Aug. 18, 2015;112(33):10437-42. doi: 10.1073/pnas. 1512503112. Epub Jul. 27, 2015.
[cited by applicant]
Schuster et al., Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas, Dec. 28, 2017,, the New England Journal of Medicine, 2017; 377; pp. 2545-2554.
[cited by applicant]
Schwartz. T cell anergy. Annu Rev Immunol. 2003;21:305-34. First published online as a Review in Advance on Dec. 5, 2002.
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-16.rag. Search run on Aug. 29, 2022. Copy retrieved Aug. 30, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?app…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-16.rai. Search run on Aug. 29, 2022. Copy retrieved Aug. 30, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?app…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-16.rapm. Search run on Aug. 29, 2022. Copy retrieved Aug. 30, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?ap…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-17.rag. Search run on Aug. 29, 2022. Copy retrieved Aug. 30, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?app…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-17.rai. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?app…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-17.rapm. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?ap…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-17.rpr. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?app…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-20.rai. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?app…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-20.rapm. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?ap…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-20.rpr. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?app…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-21.rag. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?app…
[cited by applicant]
Score Search Results Detail for Application 17862721 and Search Results 20220829_091720_us-17-862-721-21.rai. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?app…
[cited by applicant]
Sharma et al., “Novel cancer immunotherapy agents with survival benefit: recent successes and next steps,” Nat Rev Cancer, 11(11):805-812 (2011).
[cited by applicant]
Shikano et al., Membrane receptor trafficking: Evidence of proximal and distal zones conferred by two independent endoplasmic reticulum localization signals, PNAS May 13, 2003 100 (10) 5783-5788.
[cited by applicant]
Shimasaki et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy, 2012; 14: 830-840.
[cited by applicant]
Shimasaki et al., Natural killer cell reprogramming with chimeric immune receptors, Methods Mol Biol. 2013;969:203-20.
[cited by applicant]
Slavin et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood (1996) 87 (6): 2195-2204.
[cited by applicant]
Smith et al. Comparison of Biosequences. Advances in Applied Mathematics. 2:482-489 (1981).
[cited by applicant]
Smith et al. T cell activation by anti-T3 antibodies: Comparison of IgG1 and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptors. Eur J Immunol 16:478-486 (1986).
[cited by applicant]
Sommermeyer et al., Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia. Oct. 2017 ; 31(10): 2191-2199.
[cited by applicant]
Strebe et al. Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies. Journal of Immunological Methods 341 (2009) 30-40. Available online Nov. 25, 2008.
[cited by applicant]
Su et al., CRISPR-Cas9 mediated efficient PD-I disruption on human primary T cells from cancer patients, Sci Rep 6, 20070, Published: Jan. 28, 2016. 14 pages.
[cited by applicant]
Till et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119(17):3940-3950 (2012).
[cited by applicant]
Todorovska et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. Journal of Immunological Methods 248 (2001) 47-66.
[cited by applicant]
Topp et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolon…
[cited by applicant]
Torikai et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119(24):5697-5705 (2012).
[cited by applicant]
Turtle et al. CD19 Car-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126(6):2123-2138 (2016).
[cited by applicant]
U.S. Appl. No. 15/548,577 Notice of Allowance dated May 4, 2020.
[cited by applicant]
U.S. Appl. No. 15/548,577 Office Action dated Jan. 14, 2019.
[cited by applicant]
U.S. Appl. No. 15/548,577 Office Action dated Jul. 20, 2018.
[cited by applicant]
U.S. Appl. No. 15/548,577 Office Action dated Sep. 17, 2019.
[cited by applicant]
U.S. Appl. No. 16/100,117 Office Action dated Aug. 12, 2022.
[cited by applicant]
U.S. Appl. No. 16/100,117 Office Action dated Dec. 9, 2021.
[cited by applicant]
U.S. Appl. No. 16/100,117 Office Action dated May 3, 2021.
[cited by applicant]
U.S. Appl. No. 16/100,120 Office Action dated Aug. 2, 2019.
[cited by applicant]
U.S. Appl. No. 16/100,120 Office Action dated Feb. 24, 2020.
[cited by applicant]
U.S. Appl. No. 16/100,120 Office Action dated Jan. 28, 2019.
[cited by applicant]
U.S. Appl. No. 16/100,120 Office Action dated Oct. 6, 2020.
[cited by applicant]
U.S. Appl. No. 17/862,721 Office Action dated Sep. 7, 2022.
[cited by applicant]
Van Wauwe et al. Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism. J Immunol, vol. 133, No. 1, pp. 129-132 (Jul. 1984).
[cited by applicant]
Verneris et al. Natural Killer Cell Consolidation for Acute Myelogenous Leukemia: A Cell Therapy Ready for Prime Time? J Clin Oncol. Feb. 20, 2010; 28(6): 909-910.
[cited by applicant]
Verwilghen et al. Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation. Immunology 72:269-276 (1991).
[cited by applicant]
Vivier, Eric et al., Innate or adaptive immunity? The example of natural killer cells, Science (New York, N.Y.) vol. 331,6013 (2011): 44-9. doi:10.1126/science.1198687.
[cited by applicant]
Wang et al. Expression and characterization of recombinant soluble monkey CD3 molecules: mapping the FN18 polymorphic epitope. Molecular Immunology 40:1179-1188 (2004).
[cited by applicant]
Weetall et al. T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3& transgenic mice. Transplantation, vol. 73, 1658-1666, No. 10 (May 27, 2002).
[cited by applicant]
Wheeler et al. Intrabody and intrakine strategies for molecular therapy. Molecular Therapy, vol. 8, No. 3, pp. 355-366, Sep. 2003.
[cited by applicant]
Wunderlich et al. OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. Blood. 2014;123(24):e134-e144.
[cited by applicant]
Yang et al., Challenges and opportunities of allogeneic donor-derived CAR T cells, Current Opinion in Hematology, Nov. 2015; 22 (6); pp. 509-515.
[cited by applicant]
Zang et al. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13(18) pp. 5271-5279 (Sep. 15, 2007).
[cited by applicant]
Zhan et al. Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation. Cancer Immunology, Immunotherapy. Vol. 46, pp. 55-…
[cited by applicant]
Zhou, P. et al., “Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network”, The Journal of Immunology, 1998, vol. 160, pp. 1489…
[cited by applicant]
Arakawa et al. Cloning and Sequencing of the VH and YK Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody. J Biochem, vol. 120, No. 3, pp. 657-662 (1996).
[cited by applicant]
Certificate of Disclosure by Benjamin D. Grimshaw signed Dec. 15, 2021 for: Grimshaw et al. Creating a Null T Cell for Adoptive Immunotherapy. Poster. Mar. 9, 2012. One page.
[cited by applicant]
Certificate of Disclosure by David Linch signed Dec. 16, 2021 for: Grimshaw et al. Creating a Null T Cell for Adoptive Immunotherapy. Poster. Mar. 9, 2012. One page.
[cited by applicant]
Certificate of Disclosure by Martin Pule signed Dec. 15, 2021 for: Grimshaw et al. Creating a Null T Cell for Adoptive Immunotherapy. Poster. Mar. 9, 2012. One page.
[cited by applicant]
Co-pending U.S. Appl. No. 18/295,226, inventors Campana; Dario et al., filed on Apr. 3, 2023.
[cited by applicant]
Declaration by Benjamin D. Grimshaw signed Sep. 17, 2022. 2 pages.
[cited by applicant]
Nilsson et al. Retention and retrieval in the endoplasmic reticulum and the Golgi apparatus. Current Opinion in Cell Biology 1994, 6:517-521.
[cited by applicant]
Dong, et al. Modern Hematopoietic Stem Cell Transplant Therapeutics. Military Health Press. 1st Edition (2001):175-176. With English machine translation.
[cited by applicant]
GenBank Accession No. AAA83267. Version No. AAA83267.1. sFv antibody, partial [Mus musculus]. Record created Dec. 14, 1995. Page Range: 1-4. Retrieved May 15, 2024 at URL: https://www.ncbi.nlm.nih.gov/protein/AAA83267.1.
[cited by applicant]
GenBank Accession No. AAM12015. Version No. AAM12015.1. monoclonal anti-alpha-1,3-galactosyltransferase IgM heavy chain, partial [Mus musculus]. Record created Apr. 17, 2002. Page Range: 1-3. Retrieved May 15, 2024 at U…
[cited by applicant]
GenBank Accession No. ABK63997. Version No. ABK63997.1. Immunoglobulin light chain variable region, partial [Mus musculus]. Record created Nov. 25, 2006. Page Range: 1-3. Retrieved May 15, 2024 at URL: https://www.ncbi.…
[cited by applicant]
Lanitis, Evripidis, et al., A Human ErbB2-Specific T-Cell Receptor Confers Potent Antitumor Effector Functions in Genetically Engineered Primary Cytotoxic Lymphocytes. Human Gene Therapy 25:730-739 (2014).
[cited by applicant]
U.S. Appl. No. 16/943,400 Office Action dated Apr. 24, 2024.
[cited by applicant]
Tragoolpua, Khajornsak et al. Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells. BMC biotechnology 8:5, 1-13 (2008).
[cited by applicant]
U.S. Appl. No. 16/943,400 Office Action dated Feb. 5, 2025.
[cited by applicant]